Search

Displaying results 2161 - 2170 of 10000 in total
  1. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment … remain in clinical development.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.

    International brands: OraDisc A
  3. Drug

    Periciazine

    go.drugbank.com/drugs/DB01608
    Approved

    It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. … Periciazine is a phenothiazine of the piperidine group.

  4. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.

    Synonyms: 1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
  5. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.

  6. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    /L to 3690 µmol/L [A33286]. … The presence of a PEG moiety in pegvaliase-pqpz allows a reduced immune response and improved pharmacodynamic stability [A33284].

  7. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration. … [A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative.

  8. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  9. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    This drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134]. … The UK government has regulated its use, due to toxicity in those under 16 years of age.

  10. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder